Danaher (NYSE:DHR) Price Target Lowered to $285.00 at Citigroup

Danaher (NYSE:DHR) had its price target lowered by Citigroup from $305.00 to $285.00 in a report published on Monday,Benzinga reports. The firm currently has a buy rating on the conglomerate’s stock.

Several other analysts have also commented on DHR. Stephens restated an “overweight” rating and set a $315.00 price target on shares of Danaher in a research report on Wednesday, October 23rd. UBS Group dropped their target price on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Scotiabank began coverage on Danaher in a report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price target for the company. Robert W. Baird cut their price objective on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Finally, Stifel Nicolaus increased their target price on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $286.80.

Danaher Price Performance

Shares of DHR opened at $238.07 on Monday. The business’s 50-day moving average is $236.25 and its two-hundred day moving average is $254.22. The company has a market capitalization of $171.95 billion, a P/E ratio of 45.43, a P/E/G ratio of 4.33 and a beta of 0.83. Danaher has a fifty-two week low of $222.53 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period last year, the company earned $2.02 earnings per share. Danaher’s revenue for the quarter was up 3.1% compared to the same quarter last year. Research analysts predict that Danaher will post 7.5 earnings per share for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. Danaher’s dividend payout ratio is presently 20.61%.

Hedge Funds Weigh In On Danaher

Several institutional investors and hedge funds have recently bought and sold shares of DHR. Teachers Insurance & Annuity Association of America acquired a new stake in Danaher during the third quarter worth $39,000. MidAtlantic Capital Management Inc. purchased a new stake in Danaher in the 3rd quarter valued at about $40,000. FSA Wealth Management LLC acquired a new position in Danaher in the third quarter valued at about $50,000. Darwin Wealth Management LLC purchased a new position in Danaher during the third quarter worth about $55,000. Finally, Dunhill Financial LLC increased its position in shares of Danaher by 45.1% during the third quarter. Dunhill Financial LLC now owns 222 shares of the conglomerate’s stock valued at $62,000 after acquiring an additional 69 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.